BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2020 3:43:52 AM | Browse: 1016 | Download: 2236
 |
Received |
|
2020-01-26 14:03 |
|
Peer-Review Started |
|
2020-01-26 14:04 |
|
First Decision by Editorial Office Director |
|
2020-02-26 19:49 |
|
Return for Revision |
|
2020-02-26 19:49 |
|
Revised |
|
2020-03-26 03:45 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-06-05 08:00 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-06-07 03:54 |
|
Articles in Press |
|
2020-06-07 03:54 |
|
Edit the Manuscript by Language Editor |
|
2020-06-16 21:43 |
|
Typeset the Manuscript |
|
2020-07-03 12:56 |
|
Publish the Manuscript Online |
|
2020-07-07 03:43 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ping Chen, Min Yu, Ji-Liang Zhang, Wei-Yong Chen, Li Zhu, Yue Song, Cheng-Yi Jiang and Shuang Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shuang Zhang, MD, PhD, Doctor, Doctor, Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu 610041, Sichuan Province, China. shuangscu@126.com |
| Key Words |
Pulmonary sarcomatoid carcinoma; Immunotherapy; Programmed death-ligand 1; Pembrolizumab; Radiotherapy; Case report |
| Core Tip |
This is a case report of a Programmed death-ligand 1 (PD-L1)-overexpressing pulmonary sarcomatoid carcinoma (PSC) patient with a good response to pembrolizumab, indicating that pembrolizumab is an important treatment for PSC patients with PD-L1 overexpression. In this case, the patient received low-dose radiotherapy before pembrolizumab, which suggests that the combination of radiotherapy and immunotherapy may elevate treatment efficacy. |
| Publish Date |
2020-07-07 03:43 |
| Citation |
Chen P, Yu M, Zhang JL, Chen WY, Zhu L, Song Y, Jiang CY, Zhang S. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report. World J Clin Cases 2020; 8(13): 2876-2884 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i13/2876.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i13.2876 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
